Table 2.

Participant characteristics at randomization among 1,010 COAG study participants who did and did not achieve maintenance dose. ^*

	Achieved maintenance dose (n=719)	Did not achieve maintenance dose (n=291)	P *
Study intervention
Pharmacogenetic-guided dosing	370 (51)	140 (48)	0.36
Demographic characteristics
Age, years, median	58 (47, 70)	57 (45, 68)	0.086
Black race	173 (24)	100 (34)	0.001
Current smoker	94 (13)	51 (18)	0.075
Height, cm, median	173 (165, 180)	170 (163, 179)	0.79
Weight, kg, median	87 (75, 105)	88 (74, 109)	0.55
Body surface area, m2, median	2.02 (1.85, 2.20)	2.02 (1.83, 2.25)	0.72
Warfarin and other therapies
DVT or PE as primary indication	448 (62)	170 (58)	0.25
Current amiodarone use	15 (2)	8 (3)	0.49
Current fluvastatin use	2 (<1)	1 (<1)	0.99
Current enzyme inducer use	8 (1)	4 (1)	0.75
Medical history
Diabetes	161 (22)	77 (26)	0.19
Stroke	48 (7)	20 (7)	0.89
Genetic variants
CYP2C9*2			0.96
No variants	597 (83)	240 (82)
Heterozygous	114 (16)	48 (16)
Homozygous	8 (1)	3 (1)
CYP2C9*3			0.073
No variants	663 (92)	259 (89)
Heterozygous	56 (8)	31 (11)
Homozygous	0 (0)	1 (<1)
VKORC1 (VKORC1 3673G>A)			0.91
No variants (GG)	344 (48)	143 (49)
Heterozygous (AG or GA)	290 (40)	113 (39)
Homozygous (AA)	85 (12)	35 (12)
Total number of genetic variants †			0.27
0 variants	275 (38)	118 (41)
1 variant	270 (38)	94 (32)
>1 variant	174 (24)	174 (27)

DVT, deep-vein thrombosis; PE, pulmonary embolism

^*Summaries presented as n (%) unless otherwise indicated as median (25^th, 75^th percentile). P values obtained from Wilcoxon rank-sum tests for continuous variables and Fisher’s exact test for categorical variables.

^†Defined as total number of measured variants in CYP2C9*2, CYP2C9*3, and VKORC1.